Download PDF
Am J Perinatol 2021; 38(05): 428-435
DOI: 10.1055/s-0039-1698831
Review Article

Review of Prediabetes and Hypertensive Disorders of Pregnancy

Nicholas W. Carris 
1   Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy, University of South Florida, Tampa, Florida
2   Department of Family Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida
,
Chinedu K. Nwabuobi
3   Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa, Florida
,
Weiwei He
4   Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, Florida
,
Krystal Bullers
5   Shimberg Health Sciences Library, University of South Florida, Tampa, Florida
,
Roneé E. Wilson
4   Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, Florida
,
Judette M. Louis
3   Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa, Florida
,
Ronald R. Magness
3   Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa, Florida
› Author Affiliations Funding NIH HL117341 (R.R.M.) funding supported time for the completion of this article. The funding agency played no role in design, data collection, data analysis, or data interpretation or in the writing of the report or the decision to submit for publication.
› Further Information
    Permissions and Reprints

Abstract

Obesity and diabetes increase hypertensive disorders of pregnancy (HDP) risk, thus preventive interventions are heavily studied. How pregestational prediabetes and related interventions impact HDP risk is less characterized. Therefore, we searched and reviewed the literature to assess the impact on HDP risk of prediabetes and varied interventions. We identified 297 citations related to pregnancy, prediabetes, and early pregnancy interventions. We also reviewed the references and citations of included articles. We included five studies assessing HDP outcomes in women with first trimester hemoglobin A1c in the prediabetes range (5.7–6.4%). One prospective observational study demonstrated first trimester hemoglobin A1c (5.9–6.4%) is associated with increased HDP risk, while another prospective observational study and one retrospective observational study had similar trends without statistical significance. A small and underpowered randomized controlled trial demonstrated initiating gestational diabetes mellitus treatment (i.e., diet, monitoring, ± insulin) in response to first trimester hemoglobin A1c (5.7–6.4%) did not statistically reduce HDP compared with standard care. One retrospective observational study suggested metformin, when started early, may reduce HDP risk in patients with prediabetes. Pregestational prediabetes appears to increase HDP risk. Interventions (i.e., metformin, diet/glucose monitoring, and/or exercise) to reduce HDP risk require additional study with long-term follow-up.

Keywords

first trimester of pregnancy - hemoglobin A1c - hypertension - prediabetes - preeclampsia

Supplementary Material



Publication History

Received: 15 May 2019

Accepted: 07 September 2019

Article published online:
10 November 2019

© 2019. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 202: gestational hypertension and preeclampsia. Obstet Gynecol 2019; 133 (01) e1-e25
    Google Scholar
  • 2 Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367 (9516): 1066-1074
    CrossrefPubMedGoogle Scholar
  • 3 Stuart JJ, Tanz LJ, Missmer SA. et al. Hypertensive disorders of pregnancy and maternal cardiovascular disease risk factor development: an observational cohort study. Ann Intern Med 2018; 169 (04) 224-232
    CrossrefPubMedGoogle Scholar
  • 4 Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis. Hypertens Res 2017; 40 (03) 213-220
    CrossrefPubMedGoogle Scholar
  • 5 Vaught AJ, Kovell LC, Szymanski LM. et al. Acute cardiac effects of severe pre-eclampsia. J Am Coll Cardiol 2018; 72 (01) 1-11
    CrossrefPubMedGoogle Scholar
  • 6 Ohkuchi A, Hirashima C, Takahashi K, Suzuki H, Matsubara S. Prediction and prevention of hypertensive disorders of pregnancy. Hypertens Res 2017; 40 (01) 5-14
    CrossrefPubMedGoogle Scholar
  • 7 Benjamin EJ, Blaha MJ, Chiuve SE. et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 2017; 135 (10) e146-e603
    CrossrefPubMedGoogle Scholar
  • 8 American Diabetes Association. 13. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes-2018 . Diabetes Care 2018; 41 (Suppl. 01) S137-S143
    CrossrefPubMedGoogle Scholar
  • 9 American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2018 . Diabetes Care 2018; 41 (Suppl. 01) S13-S27
    CrossrefPubMedGoogle Scholar
  • 10 Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2017
    Google Scholar
  • 11 Hughes RC, Moore MP, Gullam JE, Mohamed K, Rowan J. An early pregnancy HbA1c >/=5.9% (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes. Diabetes Care 2014; 37 (11) 2953-2959
    CrossrefPubMedGoogle Scholar
  • 12 Owens DK, Lohr KN, Atkins D. et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol 2010; 63 (05) 513-523
    CrossrefPubMedGoogle Scholar
  • 13 Osmundson SS, Norton ME, El-Sayed YY, Carter S, Faig JC, Kitzmiller JL. Early screening and treatment of women with prediabetes: a randomized controlled trial. Am J Perinatol 2016; 33 (02) 172-179
    PubMedGoogle Scholar
  • 14 Rowan JA, Budden A, Ivanova V, Hughes RC, Sadler LC. Women with an HbA1c of 41-49 mmol/mol (5.9-6.6%): a higher risk subgroup that may benefit from early pregnancy intervention. Diabet Med 2016; 33 (01) 25-31
    CrossrefPubMedGoogle Scholar
  • 15 Hughes RCE, Rowan J, Williman J. Prediabetes in pregnancy, can early intervention improve outcomes? A feasibility study for a parallel randomised clinical trial. BMJ Open 2018; 8 (03) e018493
    CrossrefPubMedGoogle Scholar
  • 16 Mañé L, Flores-Le Roux JA, Benaiges D. et al. Role of first-trimester HbA1c as a predictor of adverse obstetric outcomes in a multiethnic cohort. J Clin Endocrinol Metab 2017; 102 (02) 390-397
    PubMedGoogle Scholar
  • 17 Chen L, Pocobelli G, Yu O. et al. Early pregnancy hemoglobin A1C and pregnancy outcomes: a population-based study. Am J Perinatol 2019; 36 (10) 1045-1053
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Romero R, Erez O, Hüttemann M. et al. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol 2017; 217 (03) 282-302
    CrossrefPubMedGoogle Scholar
  • 19 Syngelaki A, Sequeira Campos M, Roberge S, Andrade W, Nicolaides KH. Diet and exercise for preeclampsia prevention in overweight and obese pregnant women: systematic review and meta-analysis. J Matern Fetal Neonatal Med 2019; 32 (20) 3495-3501
    CrossrefPubMedGoogle Scholar
  • 20 Shepherd E, Gomersall JC, Tieu J, Han S, Crowther CA, Middleton P. Combined diet and exercise interventions for preventing gestational diabetes mellitus. Cochrane Database Syst Rev 2017; 11: CD010443
    PubMedGoogle Scholar
  • 21 Sweeting AN, Ross GP, Hyett J. et al. Gestational diabetes mellitus in early pregnancy: evidence for poor pregnancy outcomes despite treatment. Diabetes Care 2016; 39 (01) 75-81
    CrossrefPubMedGoogle Scholar
  • 22 Vinter CA, Tanvig MH, Christensen MH. et al. Lifestyle intervention in Danish obese pregnant women with early gestational diabetes mellitus according to WHO 2013 criteria does not change pregnancy outcomes: results from the LiP (lifestyle in pregnancy) study. Diabetes Care 2018; 41 (10) 2079-2085
    CrossrefPubMedGoogle Scholar
  • 23 Barbour LA, Feig DS. Metformin for gestational diabetes mellitus: progeny, perspective, and a personalized approach. Diabetes Care 2019; 42 (03) 396-399
    CrossrefPubMedGoogle Scholar
  • 24 Alqudah A, McKinley MC, McNally R. et al. Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. Diabet Med 2018; 35 (02) 160-172
    CrossrefPubMedGoogle Scholar
  • 25 Syngelaki A, Nicolaides KH, Balani J. et al. Metformin versus placebo in obese pregnant women without diabetes mellitus. N Engl J Med 2016; 374 (05) 434-443
    CrossrefPubMedGoogle Scholar
  • 26 Chiswick C, Reynolds RM, Denison F. et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2015; 3 (10) 778-786
    CrossrefPubMedGoogle Scholar
  • 27 Hinkle SN, Tsai MY, Rawal S, Albert PS, Zhang C. HbA1c measured in the first trimester of pregnancy and the association with gestational diabetes. Sci Rep 2018; 8 (01) 12249
    CrossrefPubMedGoogle Scholar
  • 28 Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: gestational diabetes mellitus. Obstet Gynecol 2018; 131 (02) e49-e64
    CrossrefPubMedGoogle Scholar